Work

Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple Sclerosis.

Year: 2019

Type: article

Abstract: The results support the potential therapeutic benefits of combining ponesimod with DMF to improve disease activity control in patients with MS. Additionally, the results suggest that combining ponesimod with other oral agents that have different mechanisms of action might also be therapeutically beneficial to patients with MS.

Source: Europe PMC (PubMed Central)

Authors: Laetitia Pouzol, Luca Piali, Claude Ca Bernard, Marianne M Martinic, Beat Steiner, Martine Clozel

Institutions: F. Hoffmann-La Roche AG, Idorsia Pharmaceuticals Ltd (Switzerland), Monash University, Actelion (Switzerland)

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Clinical Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W2989940110

FWCI: 1.661

Cites: 52

Cited by: 18

Related to: 10